Infant Bacterial Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Infant Bacterial Therapeutics has a total shareholder equity of SEK305.2M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK351.3M and SEK46.2M respectively.
Key information
0%
Debt to equity ratio
kr0
Debt
Interest coverage ratio | n/a |
Cash | kr329.06m |
Equity | kr305.15m |
Total liabilities | kr46.18m |
Total assets | kr351.33m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9IB's short term assets (SEK341.6M) exceed its short term liabilities (SEK46.2M).
Long Term Liabilities: 9IB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 9IB is debt free.
Reducing Debt: 9IB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9IB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 9IB has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 17.4% each year.